Found: 109
Select item for more details and to access through your institution.
Isotropic 3D fast spin-echo imaging versus standard 2D imaging at 3.0 T of the knee--image quality and diagnostic performance.
- Published in:
- 2009
- By:
- Publication type:
- journal article
SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 4, p. 1, doi. 10.2967/jnmt.123.265936
- By:
- Publication type:
- Article
SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 3, p. 176, doi. 10.2967/jnmt.123.265936
- By:
- Publication type:
- Article
Visualization of stress fractures of the foot using PET-MRI: a feasibility study.
- Published in:
- European Journal of Medical Research, 2015, v. 20, p. 1, doi. 10.1186/s40001-015-0193-6
- By:
- Publication type:
- Article
Matched-pair analysis of mCRPC patients receiving <sup>177</sup>Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.
- Published in:
- EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01143-0
- By:
- Publication type:
- Article
Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.
- Published in:
- World Journal of Urology, 2018, v. 36, n. 4, p. 603, doi. 10.1007/s00345-018-2200-3
- By:
- Publication type:
- Article
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00818-2
- By:
- Publication type:
- Article
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00818-2
- By:
- Publication type:
- Article
[<sup>18</sup>F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00808-4
- By:
- Publication type:
- Article
Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-0595-5
- By:
- Publication type:
- Article
Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysis.
- Published in:
- EJNMMI Research, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1186/s13550-019-0572-z
- By:
- Publication type:
- Article
Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2015, v. 14, n. 6, p. 895, doi. 10.5604/16652681.1171779
- By:
- Publication type:
- Article
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267234
- By:
- Publication type:
- Article
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 917, doi. 10.2967/jnumed.123.267234
- By:
- Publication type:
- Article
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of <sup>177</sup>Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 11, p. 1765, doi. 10.2967/jnumed.123.265878
- By:
- Publication type:
- Article
The Impact of PSMA PET--Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen--Targeted Radioligand Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1252, doi. 10.2967/jnumed.122.265346
- By:
- Publication type:
- Article
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1244, doi. 10.2967/jnumed.122.265259
- By:
- Publication type:
- Article
Prognostic Role of <sup>68</sup>Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 6, p. 896, doi. 10.2967/jnumed.122.264962
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 402, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1809, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1651, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with 2 metastatic castration-resistant prostate cancer (RECIP 1.0): 3 an international multicenter study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 8, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262120
- By:
- Publication type:
- Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261906
- By:
- Publication type:
- Article
Detection efficacy of <sup>18</sup>F‐rhPSMA‐7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.260091
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article